CRISPR-Cas9 screening identifies ATOX1-driven cisplatin resistance mechanisms in liver cancer and evaluates targeted inhibitor efficacy
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-03-12 13:00:33 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1038/s42003-026-09722-8
文献链接: https://www.nature.com/articles/s42003-026-09722-8
其他信息:
出版社: Springer Science and Business Media LLC
作者: Chujiao Hu; Huading Tai; Renguang Zhu; Zhengyu Shu; Guanghao Guo; Dan Ma; Shi Zuo; Lei Tang; Zhirui Zeng

